Zhaoke Ophthalmology (HKSE:06622) Moat Score: 0/10 (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06622 Zhaoke Ophthalmology Ltd HKSE:06622
47 GF Score
Price HK$2.53
GF Value HK$2.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zhaoke Ophthalmology Moat Score?

Zhaoke Ophthalmology has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Zhaoke Ophthalmology has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zhaoke Ophthalmology might have No Moat - No discernible moat.


Zhaoke Ophthalmology  (HKSE:06622) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zhaoke Ophthalmology Moat Score Related Terms

HKSE:06622
47GF Score
Zhaoke Ophthalmology Ltd HKSE:06622
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhaoke Ophthalmology (HKSE:06622) Overvalued in 2026?

Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued. The current stock price of HK$2.53 is trading 2.7% below its estimated GF Value™ of HK$2.60. GuruFocus considers Zhaoke Ophthalmology to be Fairly Valued.

Key valuation signals for HKSE:06622:

  • Moat Score: 0
  • GF Value™: HK$2.60 vs. price of HK$2.53 (2.7% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HKSE:06622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhaoke Ophthalmology Business Description

Other Exchanges 9FX:Germany
Address No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score

Get the complete analysis for HKSE:06622

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.53
Price
HK$2.60
GF Value